IDWeek Highlights | Dr. Yi Shi Comments on a Single-Center Cohort Study of Colistin Therapy for CRAB Pneumonia
Carbapenem-resistant Acinetobacter baumannii (CRAB) infection is considered one of the most challenging issues among carbapenem-resistant gram-negative bacteria (CRO) due to limited effective treatment options. Colistin, a polymyxin antibiotic used for "repurposing" in the treatment of CRAB, is one of the few choices available in China. A recent presentation at the 2023 IDWeek congress reported findings from a single-center cohort study conducted in South Korea, suggesting that colistin therapy for CRAB pneumonia lacks efficacy and is associated with an increased incidence of acute kidney injury (AKI) [1]. Dr. Yi Shi from Jinling Hospital, Nanjing University School of Medicine, provides an introduction and commentary on this study below.